Biokin Pharmaceutical T-Bren (HER2 ADC) demonstrates best-in-class potential, revealing efficacy data for treated HER2 mutated NSCLC for the first time, with a 12-month PFS rate of 73.5%
Biokin Pharmaceutical announced during the oral presentation session at the 2025 European Society for Medical Oncology Asia Congress (ESMO-Asia) the clinical research results of its independently developed flagship product T-Bren (BL-M07D1), a novel HER2 antibody-drug conjugate (HER2 ADC) targeting advanced treated non-small cell lung cancer (NSCLC) with HER2 mutations